Turn a broad statement into a specific question
When a service describes a benefit, ask what product and what outcome it means. Keep the ingredient, form and reason for treatment in view. Evidence about a different product or a different concern may not answer the question you are trying to decide.
Ask to see the source behind the statement. Read the title and the kind of document before looking for a result. Is it product information, a study report, a policy document or an advertisement? Those documents can answer different questions, so first identify what question the source can help with.
What the study tested
If a study is offered, ask the professional to describe the study group, the comparison and the unanswered questions. Ask how the study relates to your own concern. You do not need to interpret technical terms alone in order to request a clear explanation.
Keep product approval separate from other records
A listing in the National Drug Code directory is not FDA approval of a product. FDA’s own directory explanation, checked November 3, 2026, warns against treating a code as proof of approval.
Ask whether the record being shown is an approval record or only a listing. If the answer is a code, return to the product name and the type of record. A string of letters can look reassuring without answering the question you asked.
FDA registration or drug listing does not approve a facility or its medicines, under the regulation checked November 3, 2026. Approval of health care providers is not an FDA function either.
A professional license is another distinct record. Use it to check the person, and use the product record to examine the medicine. Keeping those tasks apart helps prevent a favorable answer about one part of an offer from being stretched to cover the rest.
Read claims about compounded products closely
Presenting a compound as an approved generic is misleading, according to FDA. So is claiming that trials prove the compound matches an approved product’s results. That advertising guidance was checked November 3, 2026.
Ask for the evidence about the actual preparation proposed. A paper about a familiar ingredient is not a written answer about who made this product, why it is proposed or what information accompanies it. Bring those questions back to the prescriber and pharmacy.
In its October 30, 2026 draft, HHS describes plans to take no federal action over certain compounding that meets all its conditions. This statement of plans does not change the law. The draft gives no medicine FDA approval and does not show that a peptide works for a medical condition. The distinction was checked November 3, 2026.
HHS draft policy and appendices The published draft-policy notice
If a policy announcement is offered as evidence of benefit, ask a separate question about benefit. A rule, a draft and a study are different documents. Put the answer beside the claim it is supposed to support so you can see whether the original question was answered.
Read problem reports with their limits
FDA publishes reports of unwanted problems during medicine use, called adverse events. A report alone cannot confirm the cause of someone’s problem. Nor can those reports provide a rate for a given problem; these limits were checked September 17, 2026.
An adverse event is something unwanted that happens while a medical product is being used. Ask the professional to separate reports, established label information and questions that remain open. Treat uncertainty as something to discuss, not a gap to fill with a confident assumption.
Save the claim, its source and the explanation you received. The useful result is a comparison you can follow later. If you cannot tell which evidence belongs to which product, ask for that link to be made clear before making the care decision.